In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 26 to 50 of 404

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701	Technology appraisal guidance	TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]	Technology appraisal guidance	23 July 2025
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]	Technology appraisal guidance	TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]	Technology appraisal guidance	TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]	Technology appraisal guidance	TBC
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]	Technology appraisal guidance	TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]	Technology appraisal guidance	TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]	Technology appraisal guidance	TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497	Technology appraisal guidance	TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]	Technology appraisal guidance	TBC
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]	Technology appraisal guidance	25 June 2025
Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour	Interventional procedures guidance	16 April 2025
Bed frames for adults in acute settings	Health technology evaluation	28 May 2025
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]	Technology appraisal guidance	TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212	Technology appraisal guidance	5 March 2025
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211	Technology appraisal guidance	19 March 2025
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]	Technology appraisal guidance	TBC
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266	Technology appraisal guidance	16 July 2025
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462	Technology appraisal guidance	11 September 2025
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]	Technology appraisal guidance	4 December 2024
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]	Technology appraisal guidance	20 February 2019
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]	Technology appraisal guidance	TBC

Results per page

10
25
50
All